← Leaderboards
Changcheng Zhou
University Of California Riverside
$12,173,776
Attributed
$13,241,595
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,241,595 · 9
By mechanism
R01$7,871,992 · 4
R35$2,536,895 · 1
P20$1,302,422 · 2
P30$1,117,317 · 1
R21$412,969 · 1
Top collaborators
- Hong Chen3 shared
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicCardiovascular DiseasesRegulationAtherosclerosisCellsMediatingMouse ModelPilot ProjectsLinkAffectDietIn VivoPregnane X ReceptorXenobioticsCardiovascular Disorder RiskAgonistLipidsSensorDiabetes MellitusIn VitroMorbidity - Disease RateDyslipidemiasMolecularObesity
Grant awards (35)
Role of PXR in EDC-induced cardiovascular disease$841,485
R35 · FY2025 · ES · contact PI
Role of PXR in drug-elicited cardiovascular disease$712,001
R01 · FY2025 · HL · contact PI
Role of PXR in EDC-induced cardiovascular disease$846,150
R35 · FY2024 · ES · contact PI
Role of PXR in drug-elicited cardiovascular disease$697,761
R01 · FY2024 · HL · contact PI
Role of PXR in EDC-induced cardiovascular disease$849,260
R35 · FY2023 · ES · contact PI
Role of PXR in drug-elicited cardiovascular disease$725,876
R01 · FY2023 · HL · contact PI
Core D - Energy Balance and Body Composition Core$352,317
P30 · FY2022 · GM · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia and atherosclerosis$349,875
R01 · FY2022 · ES · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia and atherosclerosis$349,875
R01 · FY2021 · ES · contact PI
Core D - Energy Balance and Body Composition Core$191,250
P30 · FY2021 · GM · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia and atherosclerosis$349,875
R01 · FY2020 · ES · contact PI
Core D - Energy Balance and Body Composition Core$191,250
P30 · FY2020 · GM · contact PI
Role of IKKβ in obesity and atherosclerosis$376,250
R01 · FY2019 · HL · contact PI
Core D - Energy Balance and Body Composition Core$191,250
P30 · FY2019 · GM · contact PI
Role of IKKβ in obesity and atherosclerosis$376,250
R01 · FY2018 · HL · contact PI
A novel mechanism for ART-associated dyslipidemia and atherosclerosis$250,000
R01 · FY2018 · HL · contact PI
Core D - Energy Balance and Body Composition Core$191,250
P30 · FY2018 · GM · contact PI
A novel mechanism for ART-associated dyslipidemia and atherosclerosis$123,523
R01 · FY2018 · HL · contact PI
Role of IKKβ in obesity and atherosclerosis$376,250
R01 · FY2017 · HL · contact PI
A novel mechanism for ART-associated dyslipidemia and atherosclerosis$373,523
R01 · FY2017 · HL · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia$338,625
R01 · FY2017 · ES · contact PI
The role of IKKÃ in linking obesity to adipose tissue inflammation and adipogene$263,375
P20 · FY2017 · GM · contact PI
Role of IKKβ in obesity and atherosclerosis$376,250
R01 · FY2016 · HL · contact PI
A novel mechanism for ART-associated dyslipidemia and atherosclerosis$373,523
R01 · FY2016 · HL · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia$338,625
R01 · FY2016 · ES · contact PI
The role of IKKB in linking obesity to adipose tissue inflammation and adipogene$263,375
P20 · FY2016 · GM · contact PI
A novel mechanism for ART-associated dyslipidemia and atherosclerosis$373,523
R01 · FY2015 · HL · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia$338,625
R01 · FY2015 · ES · contact PI
Mechanisms of atherogenic effects of bisphenol A$187,969
R21 · FY2015 · ES · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia$339,242
R01 · FY2014 · ES · contact PI
The role of IKKB in linking obesity to adipose tissue inflammation and adipogene$262,567
P20 · FY2014 · GM · contact PI
Mechanisms of atherogenic effects of bisphenol A$225,000
R21 · FY2014 · ES · contact PI
Endocrine disruptor mediated activation of PXR causes dyslipidemia$332,520
R01 · FY2013 · ES · contact PI
The role of IKKB in linking obesity to adipose tissue inflammation and adipogene$262,500
P20 · FY2013 · GM · contact PI
IKKBETA LINKS MACROPHAGE INFLAMMATION TO OBESITY-INDUCED ATHEROSCLEROSIS$250,605
P20 · FY2011 · RR · contact PI